Keryx Biopharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported total revenues of $21,751,000 against $11,819,000 a year ago. Operating loss was $22,752,000 against $23,110,000 a year ago. Loss before income taxes was $22,530,000 against $22,996,000 a year ago. Net loss was $21,896,000 against $23,016,000 a year ago. Basic and diluted net loss per common share was $0.18 against $0.21 a year ago. Total revenues for the first quarter of 2018 consist of approximately $20.6 million in net U.S. Auryxia product sales, as compared to $10.5 million in the first quarter of 2017. Revenue growth in the first quarter of 2018, as compared to the first quarter of 2017, was driven by an increase in Auryxia prescription and tablet demand, partially offset, by a reduction in the net price realized per tablet due to an increase in the gross-to-net adjustment.